Losartan/hydrochlorothiazide combination therapy surpasses high-dose angiotensin receptor blocker in the reduction of morning home blood pressure in patients with morning hypertension

Acta Medica Okayama

Volumn 66, Issue 6, 2012, Pages 449-459

  Hanayama, Yoshihisa ^a   Uchida, Haruhito Adam ^a   Nakamura, Yoshio ^a   Makino, Hirofumi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Angiotensin II; Hydrochlorothiazide; Hyperuricemia; Losartan; Morning blood pressure

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE, LOSARTAN DRUG COMBINATION; LOSARTAN;

AGED; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; DRUG EFFECT; FEMALE; HUMAN; HYPERTENSION; MALE; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; DRUG COMBINATIONS; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; LOSARTAN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84873720698     PISSN: 0386300X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Lawes CM, Rodgers A, Bennett DA, Parag V, Suh I, Ueshima H and MacMahon S; Asia Pacific Cohort Studies Collaboration: Blood pressure and cardiovascular disease in the Asia Pacific region. J Hypertens (2003) 21: 707-716.
2. Lida M, Ueda K, Okayama A, Kodama K, Sawai K, Shibata S. Tanaka S, Keijnkai T, Horibe H, Minowa M, Yanagawa H and Hashimoto T; Nippon Data 80 Research Group: Impact of elevated blood pressure on mortality from all causes, cardiovascular dis-eases, heart disease and stroke among Japanese: 14 year follow-up of randomly selected population from Japanese -- Nippon data 80. J Hum Hypertens (2003) 17: 851-857.
3. Haroun MK, Jaar BG, Hoffman SC, Comstock GW, Klag MJ and Coresh J: Risk factors for chronic kidney disease: a prospective study of 23,534 men and women in Washington County, Maryland. J Am Soc Nephrol (2003) 14: 2934-2941.
4. Tanizaki Y, Kiyohara Y, Kato I, Iwamoto H, Nakayama K. Shinohara N, Arima H, Tanaka K, Ibayashi S and Fujishima M Incidence and risk factors for subtypes of cerebral infarction in a general population: the Hisayama study. Stroke (2000) 31: 2616-2622.
5. Ogihara T, Kikuchi K, MatsuokaH, FujitaT, Higaki J, Horiuchi M Imai Y, Imaizumi T, Ito S, Iwao H, Kario K, Kawano Y, Kim-Mitsuyama S, Kimura G, Matsubara H, Matsuura H, Naruse M Saito I, Shimada K, Shimamoto K, Suzuki H, Takishita S Tanahashi N, Tsuchihashi T, Uchiyama M, Ueda S, Ueshima H Umemura S, Ishimitsu T and Rakugi H: The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res (2009) 32: 103-107.
6. Turnbull F; Blood Pressure Lowering Treatment Trialists' Collabo-ration: Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed over-views of randomised trials. Lancet (2003) 362: 1527-1535.
7. Arima H, Tanizaki Y, Kiyohara Y, Tsuchihashi T, Kato I, Kubo M Tanaka K, Ohkubo K, Nakamura H, Abe I, Fujishima M and lida M: Validity of the JNC VI recommendations for the management of hypertension in a general population of Japanese elderly: The Hisayama study. Arch Intern Med (2003) 163: 361-366.
8. Murakami Y, Hozawa A, Okamura T and Ueshima H; Evidence for Cardiovascular Prevention From Observational Cohorts in Japan Research Group (EPOCH-JAPAN): Relation of blood pressure and all-cause mortality in 180,000 Japanese participants: pooled analysis of 13 cohort studies. Hypertension (2008) 51: 1483-1491.
9. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R: Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V: Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E: Ambrosioni E, Lindholm LH, Viigimaa M, Adamopoulos S Bertomeu V, Clement D, Farsang C, Gaita D, Lip G, Mallion JM Manolis AJ, Nilsson PM, O'Brien E, Ponikowski P, Redon J Ruschitzka F, Tamargo J, van Zwieten P, Waeber B and Williams B: 2007 Guidelines for the Management of Arterial Hypertension The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2007) 25: 1105-1187.
10. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA: Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr and Roccella EJ: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension (2003) 42: 1206-1252.
11. Townsend R, Haggert B, Liss C and Edelman JM: Efficacy and tolerability of losartan versus enalapril alone or in combination with hydrochlorothiazide in patients with essential hypertension. Clin Ther (1995) 17: 911-923.
12. Shargorodsky M, Hass E, Boaz M, Gavish D and Zimlichman R: High dose treatment with angiotensin II receptor blocker in patients with hypertension: differential effect of tissue protection versus blood pressure lowering Atherosclerosis (2008) 197: 303-310.
13. Meier P, Maillard MP, Meier JR, Tremblay S, Gauthier T and Burnier M: Combining blockers of the renin-angiotensin system or hcreasing the dose of an angiotensin II receptor antagonist in pro-teinuric patients: a randomized triple-crossover study. J Hypertens (2011)29: 1228-1235.
14. Kario K and White WB: Early morning hypertension: what does it contribute to overall cardiovascular risk assessment? J Am Soc Hypertens (2008) 2: 397-402.
15. Sakaguchi K, Horimatsu T, Kishi M, TakedaA, Ohnishi Y, Koike T. Fujisawa T and Maeda M: Isolated home hypertension in the morning is associated with target organ damage in patients with type 2 diabetes. J Atheroscler Thromb (2005) 12: 225-231.
16. Hermida RC, Ayala DE, Mojon A and Fernandez JR: Influence of time of day of blood pressure-lowering treatment on cardiovascular risk in hypertensive patients with type 2 diabetes. Diabetes Care (2011)34: 1270-1276.
17. Metoki H, Ohkubo T and Imai Y: Diurnal blood pressure variation and cardiovascular prognosis in a community-based study of Ohasama, Japan. Hypertens Res (2010) 33: 652-656.
18. Flack JM, Saunders E, Gradman A, Kraus WE, Lester FM, Pratt JH, Alderman M, Green S, Vargas R, Espenshade M, Ceesay P. Alexander J Jr and Goldberg A; Study Group for Losartan in African Americans with Hypertension: Antihypertensive Efficacy and Safety of Losartan Alone and in Combination with Hydrochlorothiazide in Adult African Americans with Mild to Moderate Hypertension. Clin Ther (2001) 23: 1193-1208.
19. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K. Yamagata K, Tomino Y, Yokoyama H and Hishida A; Collaborators developing the Japanese equation for estimated GFR Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis (2009) 53: 982-992.
20. OgawaS, Takeuchi K, Mori T, Nako K, Tsubono Yand Ito S: Effects of monotherapy of temocapril or candesartan with dose increments or combination therapy with both drugs on the suppression of dia-betic nephropathy. Hypertens Res (2007) 30: 325-334.
21. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S and Wedel H; LIFE Study Group: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (2002) 359: 995-1003.
22. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B Trenkwalder P and Zanchetti A; SCOPE Study Group: The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens (2003)21: 875-886.
23. Izzo JL Jr, Weintraub HS, Duprez DA, Purkayastha D, Zappe D Samuel R and Cushman WC: Treating systolic hypertension in the very elderly with valsartan-hydrochlorothiazide vs. either mono-therapy: ValVET primary results. J Clin Hypertens (Greenwich) (2011) 13: 722-730.
24. Makita S, Abiko A, Naganuma Y, Tamada M and Nakamura M Efficacy of low-dose hydrochlorothiazide in combination with telm-sartan on early morning blood pressure in uncontrolled hypertensive patients. Clin Exp Hypertens. (2009)31: 105-115.
25. Chrysant SG, Weber MA, Wang AC and Hinman DJ: Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am J Hypertens (2004) 17 252-259.
26. Manolis AJ, Grossman E, Jelakovic B, Jacovides A, Bernhardi DC, Cabrera WJ, Watanabe LA, Barragan J, Matadamas N Mendiola A, Woo KS, Zhu JR, Mejia AD, Bunt T, Dumortier T and Smith RD: Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension. Losartan Trial Investigators. Clin Ther (2000) 22: 1186-1203.
27. Bonner G, Landers B and Bramlage P: Candesartan cilexetil/ hydrochlorothiazide combination treatment versus high-dose can-desartan cilexetil monotherapy in patients with mild to moderate cardiovascular risk (CHILI Triple T). Vase Health Risk Manag (2011) 7: 85-95.
28. Hashimoto J, Hirayama H, Hanasawa T, Watabe D, Asayama K: Metoki H, Kikuya M, Ohkubo T, Totsune K and Imai Y: Efficacy of combination antihypertensive therapy with low-dose indapamide assessment by blood pressure self-monitoring at home. Clin Exp Hypertens (2005) 27: 331-341.
29. Takami T: Evaluation of arterial stiffness in morning hypertension under high-dose valsartan compared to valsartan plus low-dose diuretic. Hypertens Res (2009) 32: 1086-1090.
30. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED Kochar MS, Hamburger RJ, Fye C, Lakshman R, Gottdiener J Ramirez EA and Henderson WG: Single-drug therapy for hyperten-sion in men. A comparison of six antihypertensive agents with pla-cebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med (1993) 328: 914-921.
31. Matsui Y, Eguchi K, Shibasaki S, Ishikawa J, Shimada K and Kario K: Morning hypertension assessed by home monitoring is a strong predictor of concentric left ventricular hypertrophy in patients with untreated hypertension J Clin Hypertens (Greenwich) (2010) 12: 776-783.
32. Shibamiya T, ObaraT, Ohkubo T, Shinki T, Ishikura K, Yoshida M Satoh M, Hashimoto T, Hara A, Metoki H, Inoue R, Asayama K: Kikuya M and Imai Y: Electrocardiographic abnormalities and home blood pressure in treated elderly hypertensive patients: Japan home versus office blood pressure measurement evaluation in the elderly (J-HOME-Elderly) study. Hypertens Res (2010) 33: 670-677.
33. Yano Y, Hoshide S, Inokuchi T, Kanemaru Y, Shimada K and Kario K: Association between morning blood pressure surge and cardiovascular remodeling in treated elderly hypertensive subjects. Am J Hypertens (2009) 22: 1177-1182.
34. Shintani Y, Kikuya M, Hara A, Ohkubo T, Metoki H, Asayama K: houe R, Obara T, Aono Y, Hashimoto T, Hashimoto J, Totsune K: Hoshi H, Satoh H and Imai Y: Ambulatory blood pressure, blood pressure variability and the prevalence of carotid artery alteration the Ohasama study. J Hypertens (2007) 25: 1704-1710.
35. Uchida H, NakamuraY, KaiharaM, Sugimoto T, Norii H, Sasaki M Sato H and Makino H: Practical efficacy of telmisartan for decreas-ing morning home blood pressure and pulse wave velocity in patients with mild-to-moderate hypertension. Hypertens Res (2004) 27: 545-550.
36. Hoshino A, Nakamura T and Matsubara H: The bedtime adminis-tration ameliorates blood pressure variability and reduces urinary albumin excretion in amlodipine-olmesartan combination therapy. Clin Exp Hypertens (2010) 32: 416-422.
37. Lim JS and Kwon HM: Risk of "silent stroke" in patients older than 60 years: risk assessment and clinical perspectives. Clin Interv Aging (2010) 5: 239-251.
38. Kario K, Matsui Y, Shibasaki S, Eguchi K, Ishikawa J, Hoshide S Shikawa S, Kabutoya T, Schwartz JE, Pickering TG and Shimada K: An alpha-adrenergic blocker titrated by self-measured blood pressure recordings lowered blood pressure and microalbuminuria in patients with morning hypertension: the Japan Morning Surge-1 Study. J Hypertens (2008) 26: 1257-1265.
39. Fujiwara T, NishimuraT, Ohkuko T and Imai Y; HOMED-BP Study Group: Rationale and design of Homed-BP Study: hypertension objective treatment based on measurement by electrical devices of blood pressure study Blood Press Monit (2002) 7: 77-82.
40. Burnier M, Roch-Ramel F and Brunner HR: Renal effects of angio-tensin II receptor blockade in normotensive subjects Kidney Int (1996)49: 1787-1790.
41. Roch-Ramel F, Guisan B and Diezi J: Effects of uricosuric and antiuricosuric agents on urate transport in human brush-border membrane vesicles. J Pharmacol Exp Ther (1997) 280: 839-845.
42. Hamada T, Ichida K, Hosoyamada M, Mizuta E, Yanagihara K. Sonoyama K, Sugihara S, Igawa O, Hosoya T, Ohtahara A. Shigamasa C, Yamamoto Y, Ninomiya H and Hisatome I: Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients. Am J Hypertens (2008) 21: 1157-1162.
43. Uzu T and Kimura G: Diuretics shift circadian rhythm of blood pressure from nondipper to dipper in essential hypertension. Circu-lation (1999) 100: 1635-1638.